Opeyemi Ernest Oludada

Opeyemi Ernest Oludada

Auto-generated profile, based on publicly available information

Opeyemi Ernest Oludada

University of Calgary

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2023 in EMBO Molecular Medicine
Verified
Journal Article
Open access
OOOpeyemi Ernest Oludada
Opeyemi Ernest Oludada
GCGiulia Costa
Giulia Costa
CAClare Burn Aschner
Clare Burn Aschner
AOAnna S Obraztsova
Anna S Obraztsova
KPKatherine Prieto
Katherine Prieto
HWHedda Wardemann
Hedda Wardemann
Human monoclonal antibodies (mAbs) against the central repeat and junction domain of Plasmodium falciparum circumsporozoite protein (PfCSP) have been studied extensively to guide malaria vaccine design compared to antibodies against the PfCSP C terminus. Here, we describe the molecular characteristics and protective potential of 73 germline and mutated human mAbs against the highly immunogenic PfCSP C‐terminal domain. Two mAbs recognized linear epitopes in the C‐terminal linker with sequence similarity to repeat and junction motifs, whereas all others targeted conformational epitopes in the α‐thrombospondin repeat (α‐TSR) domain. Specificity for the polymorphic Th2R/Th3R but not the conserved RII+/CS.T3 region in the α‐TSR was associated with IGHV3‐21 / IGVL3‐21 or IGLV3‐1 gene usage. Although the C terminus specific mAbs showed signs of more efficient affinity maturation and class‐switching compared to anti‐repeat mAbs, live sporozoite binding and inhibitory activity was limited to a single C‐linker reactive mAb with cross‐reactivity to the central repeat and junction. The data provide novel insights in the human anti‐C‐linker and anti‐α‐TSR antibody response that support exclusion of the PfCSP C terminus from malaria vaccine designs.

19 October 2022 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
OOOpeyemi Ernest Oludada
Opeyemi Ernest Oludada
TITemitayo Opemipo Idowu
Temitayo Opemipo Idowu
YJYoukyoung Jeon
Youkyoung Jeon
Inhak ChoiInhak Choi
Inhak Choi

16 October 2026 in Research Square
Verified
Preprint
Open access
PDF file
AKAlyson Kelvin
Alyson Kelvin
OOOpeyemi Oludada
Opeyemi Oludada
MFMagen Francis
Magen Francis
BIBaweleta Isho
Baweleta Isho
SSSalma Sheikh-Mohamed
Salma Sheikh-Mohamed
GMGustavo Martinez
Gustavo Martinez
SARS-CoV-2 secondary infections remain a persistent challenge even though individuals have previous immunity from natural infection or vaccination. Yet, the cellular mechanisms that determine whether a secondary exposure is rapidly controlled by pre-existing immunity and results in sterilizing protection or progresses to productive infection and disease remain poorly understood. Using homologous and heterologous secondary-challenge experimental strategies in C57BL/6J mice, we show that protection against a homologous SARS-CoV-2 Alpha secondary challenge in previously infected mice is time-limited, remaining durable through 56 days post-primary infection, with breakthrough infection on day 84 post-primary infection. This loss of protection was not associated with waning neutralizing antibody titers but instead correlated with progressive contraction of T follicular helper cells and germinal center B cells in the mediastinal lymph node. In contrast, heterologous Beta secondary exposure in Alpha-previously infected mice consistently failed to mount a robust germinal center response despite mobilizing comparable or greater numbers of immune cells than homologous re-challenge. Instead, RNA-seq and flow cytometry analyses revealed that this response was associated with an inflammatory extrafollicular B cell response characterized by reduced Bcl6 and Aicda expression and concomitant robust upregulation of Il6 . Taken together, these findings identify the germinal center recall response in the mediastinal lymph node as an important cellular correlate of SARS-CoV-2 secondary immunity and carry direct implications for the timing of booster immunization and the design of cross-variant vaccines.

26 September 2026 in npj Vaccines
Verified
Journal Article
Open access
PDF file
OOOpeyemi Ernest Oludada
Opeyemi Ernest Oludada
MFMagen E. Francis
Magen E. Francis
AKAnuj Kumar
Anuj Kumar
GMGustavo Sganzerla Martinez
Gustavo Sganzerla Martinez
MFMary K. Foley
Mary K. Foley
AKAlyson A. Kelvin
Alyson A. Kelvin
Influenza viruses circulate annually in humans, accumulating mutations in the viral genome. In real-world conditions, people develop an immune history from multiple influenza virus infections and vaccinations, yet most experimental studies utilize naïve hosts to investigate viral pathogenesis or vaccine efficacy; a scenario that does not reflect actual human exposure and immune responses. Here, we report that mice previously infected with the mouse-adapted H1N1 virus mounted an increased antibody response after vaccination with the split virion quadrivalent seasonal influenza vaccine. Antibodies targeting the H1 antigen component of the vaccine in H1N1 preimmune mice had titers peaking at a log2 HAI titer of 8 versus 2 in naïve-vaccinated mice at 14 days post-vaccination, whereas H3N2 pre-immune mice showed no improved vaccine responses. Increased total serum class-switched IgG subclass concentrations in the H1N1 preimmune-vaccinated mice accompanied protection from weight loss and mortality when these mice were challenged with an H1N1 pandemic 2009 strain. Temporal sampling and analysis of RNA from mediastinal lymph nodes from preimmune mice by RNA-seq at time points following vaccination revealed distinct regulation of lymphocyte and germinal center-specific genes, including Bcl6, an essential gene for germinal-center-dependent B-cells. Taken together, H1N1 A/FM/1/1947 preimmunity led to a more efficient vaccine response accompanied by altered expression of germinal center-associated genes in the mediastinal lymph node, with implications for future vaccine design.

24 July 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
RMRajagopal Murugan
Rajagopal Murugan
AHAnton Hanke
Anton Hanke
OOOpeyemi Ernest Oludada
Opeyemi Ernest Oludada
GCGiulia Costa
Giulia Costa
YFYevel Flores-Garcia
Yevel Flores-Garcia
HWHedda Wardemann
Hedda Wardemann
The protective capacity of antibodies targeting circumsporozoite protein on sporozoites of the malaria parasite Plasmodium falciparum (PfCSP) is linked to high affinity and cross-reactivity with the PfCSP central repeat domain and N-terminal junction. However, the role of somatic hypermutation (SHM) in the development of such antibodies remains unclear. Here we define the contributions of SHM to the high affinity and strong repeat and N-junction cross-reactivity of the potent anti-PfCSP monoclonal antibody (mAb) 4493 and of similar antibodies with shared SHM and affinity maturation trajectories. Molecular dynamics simulations reveal that SHM reduces the flexibility of the unbound mAb 4493 but increases the flexibility of the antigen-bound complex, thereby lowering the entropic cost for antigen binding. Furthermore, we identify an inverse relation between antibody affinity and serum stability, which limits the protective capacity of these antibodies. Our study provides molecular level evidence for the different roles that the SHM process plays in increasing VH3-49+Vκ3-20 antibody affinity and cross-reactivity and demonstrates how antibody affinity maturation can negatively impact antibody stability and thereby function.